Maravai LifeSciences Holdings, Inc.(MRVI)
$8.54—
Maravai LifeSciences Holdings, Inc.(MRVI)
NASDAQ
$8.54—
Hold13 analysts
Target $6.00-29.7%
Key Metrics
TTMMarket Cap$4.49B
Revenue TTM$208.78M
Rev Growth FY26E+13.9%
Rev Growth YoY-3.3%
Price / Sales21.5x
Net Income TTM-$77.39M
Free Cash Flow-$35.11M
Gross Margin34.6%
Operating Margin46.0%
Net Margin-37.1%
Return on Equity-35.4%
Return on Assets-12.8%
Debt / Equity (MRQ)0.86
Current Ratio (MRQ)4.05
EPS TTM$-0.52
PRICE
Prev Close
8.90
Open
8.76
Day Range8.53 – 8.98
8.53
8.98
52W Range2.29 – 9.42
2.29
9.42
88% of range
50-Day MA
6.45(+32.5%)
200-Day MA
4.35(+96.5%)
VOLUME & SIZE
Avg Volume
3.4M
FUNDAMENTALS
P/E (TTM)
-45.0x
Not profitable
EPS (TTM)
—
Div Yield (TTM)
No dividend
Beta
0.95
Market-like
TECHNICAL
RSI (14)
79
Overbought
Upcoming Events
EEarnings Report
In 70 days
Nov 5
DEx-Dividend
In 90 days
Nov 25
PDividend Pay
In 116 days
Dec 21
MRVI News
About
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are global leaders in providing products and services into the fields of nucleic acid production, biologics safety testing, and protein detection to many of the world's leading biopharma, vaccine, diagnostics, and cell and gene therapy companies.
Bernd BrustChief Executive Officer & Director
Kurt OreshackExecutive Vice President, General Counsel & Secretary
Christine DolanExecutive Vice President & GM of Cygnus Technologies
Rajesh J. AsorpotaExecutive Vice President & Chief Financial Officer
Judith A. SoleckiSenior VP & Chief Human Resources Officer
Kate E. BroderickExecutive Vice President
Christopher BenoitExecutive Vice President & Advisor
Robert Andrew EckertChairman of the Board
Chanfeng ZhaoSenior Vice President & Chief Scientific Officer
Debra HartSenior Director of Investor Relations